<DOC>
	<DOCNO>NCT01752205</DOCNO>
	<brief_summary>The purpose study test safety effectiveness erlotinib chemoradiotherapy patient unresectable esophageal gastro-esophageal squamous cancer .</brief_summary>
	<brief_title>Paclitaxel Plus Radiation With Erlotinib Treat Esophageal Squamous Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Histologically confirm squamous cell carcinoma esophagus Esophagogastric Junction 2 . Age &gt; = 18 3 . ECOG PS 02 4 . Ineligibility surgery 5 . No prior palliative therapy 6 . At least one bidimensionally measurable disease define RECIST ver 1.1 7 . Adequate organ function treatment Absolute neutrophil count ( ANC ) &gt; =1000cells/mm3 Platelets &gt; =100000 cells/mm3 Estimated creatinine clearance &gt; =50mL/min , serum creatinine &lt; 1.5 x institution upper limit normal Bilirubin= &lt; 1.5 x upper limit normal ( ULN ) AST ( SGOT ) = &lt; 2.5 x ULN ( 5.0xULN hepatic metastasis ) ALT ( SGPT ) = &lt; 2.5 x ULN ( 5.0xULN hepatic metastasis ) 12Lead electrocardiogram ( ECG ) normal trace nonclinically significant change require medical intervention QTc interval = &lt; 470 msec without history Torsades de Points symptomatic QTc abnormality LVEF ( MUGA echocardiogram ) &gt; =50 % . 8 . The patient provide sign informed consent amenable compliance protocol schedule test . 1 . Previous treatment small molecule EGFR tyrosine kinase inhibitor 2 . Any major operation within 4 week baseline disease assessment 3 . Any clinically significant gastrointestinal abnormality may impair intake absorption study drug 4 . CNS metastasis continuous corticosteroid use within 4 week baseline disease assessment 5 . Patients know interstitial lung disease 6 . Patients uncontrolled significant cardiovascular disease ( AMI within 12 month , Unstable angina within 6 month , NYHA Class III , IV Congestive heart failure leave ventricular ejection fraction local institutional low limit normal 45 % , Congenital long QT syndrome , Any significant ventricular arrhythmia , Any uncontrolled second third degree heart block , Uncontrolled hypertension ) 7 . Previous concurrent malignancy except basal squamous cell skin cancer and/or situ carcinoma cervix , solid tumor treat curatively without evidence recurrence least 5 year prior study entry . 8 . Pregnant breastfeed woman 9 . Other severe acute chronic medical condition laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation trial result , judgment investigator , would make patient inappropriate entry trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Esophageal Squamous Carcinoma</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Chemoradiotherapy</keyword>
</DOC>